表紙：嚢胞性線維症の市場規模、シェア、成長分析、治療方法別、投与経路別、薬剤クラス別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1789254

嚢胞性線維症の市場規模、シェア、成長分析、治療方法別、投与経路別、薬剤クラス別、地域別 - 産業予測、2025年～2032年

Cystic Fibrosis Market Size, Share, and Growth Analysis, By Treatment Method (Medication, Devices), By Route of Administration (Oral, Inhaled), By Drug Class, By Region - Industry Forecast 2025-2032

出版日: 2025年08月07日
発行: SkyQuest
ページ情報: 英文 181 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 783,976円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 917,104円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,050,232円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.92円

全表示
概要
目次

概要

サンプル依頼リストに入れる

嚢胞性線維症の世界市場規模は2023年に61億米ドルと評価され、2024年の67億米ドルから2032年には205億米ドルに成長し、予測期間（2025～2032年）のCAGRは13％で成長する見通しです。

嚢胞性線維症の世界市場は、罹患率の上昇、治療オプションの進歩、新生児スクリーニングイニシアチブの拡大、疾患に対する意識の高まりなどを背景に、大きく成長する見通しです。研究開発努力の増加は、政府の強力な支援プログラムとともに、嚢胞性線維症膜貫通型伝導調節因子（CFTR）モジュレーターの急増につながっています。スクリーニングによる早期発見は、治療効果を著しく向上させています。さらに、変異に特異的な治療法へのシフトが進んでいる一方で、ヘルスケア支出の増加や効果的な患者支援活動により、ケア提供の強化に向けた新たな機会がもたらされています。吸入装置や薬剤製剤の革新は治療の選択肢を広げています。しかし、高額な治療費、限られた患者数、開発期間の長期化、未開発地域におけるアクセスの問題などの課題は、引き続き市場の進展に影響を与えています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Vertex Pharmaceuticals Incorporated（United States）
AbbVie Inc.（United States）
F. Hoffmann-La Roche Ltd.（Switzerland）
Novartis AG（Switzerland）
Gilead Sciences, Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（United States）
Chiesi Farmaceutici S.p.A.（Italy）
Alcresta Therapeutics, Inc.（United States）
Laurent Pharmaceuticals Inc.（Canada）
Pulmocide Ltd.（United Kingdom）
Zambon S.p.A.（Italy）
Sanofi S.A.（France）
Translate Bio（United States）
Armata Pharmaceuticals, Inc.（United States）

結論と提言

Product Code: SQMIG35H2357

Global Cystic Fibrosis Market size was valued at USD 6.1 Billion in 2023 and is poised to grow from USD 6.7 Billion in 2024 to USD 20.5 Billion by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The global cystic fibrosis market is poised for significant growth driven by rising incidence rates, advancements in therapeutic options, expanded newborn screening initiatives, and heightened awareness of the disease. Increased research and development efforts have led to a surge in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, alongside robust government support programs. Early detection through screening has notably improved treatment efficacy. Additionally, a shift towards mutation-specific therapies is gaining traction, while rising healthcare expenditures and effective patient advocacy initiatives present new opportunities for enhanced care delivery. Innovations in inhalation devices and drug formulations are expanding treatment options. However, challenges such as high treatment costs, limited patient populations, lengthy development timelines, and access issues in underdeveloped regions continue to impact market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cystic Fibrosis Market Segments Analysis

The global cystic fibrosis market is segmented by treatment method, route of administration, and drug class. Based on treatment methods, the market is segmented into medication and devices. Based on the route of administration, the market is segmented into oral and inhaled. Based on drug class, the market is segmented into pancreatic enzyme supplements, mucolytic, bronchodilators, antibiotics, and CFTR modulators. Based on region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa.

Driver of the Global Cystic Fibrosis Market

Advancements in genetic research and innovative therapies, particularly CFTR modulators, are significantly enhancing the health and longevity of individuals affected by cystic fibrosis. These modern treatments uniquely address the fundamental biological underpinnings of the disease rather than merely alleviating its symptoms or associated complications. This targeted approach not only promises better health outcomes but also fosters greater acceptance and integration of these therapies within healthcare systems globally. As the medical landscape evolves, the emphasis on treating the root cause of cystic fibrosis is set to propel increased demand for these transformative treatments, ultimately benefiting patients worldwide.

Restraints in the Global Cystic Fibrosis Market

The global market for cystic fibrosis is significantly hindered by the high costs associated with advanced therapies, particularly CFTR modulators, which are often prohibitive for patients. Many insurance providers show reluctance to offer coverage or reimbursements for these treatments, leading to limited access. This issue is particularly acute in low- and middle-income countries, where the lack of financial support contributes to substantially lower treatment rates. Consequently, these barriers to access stifle overall growth in the cystic fibrosis market, creating disparities in treatment availability and outcomes for patients across different regions.

Market Trends of the Global Cystic Fibrosis Market

The global cystic fibrosis market is witnessing significant transformation driven by advancements in gene editing technologies and innovative CFTR modulators. These emerging therapies target the root genetic causes of the disease, marking a shift from traditional treatment methods. Increased investments in research and development are fostering a wave of mutation-specific approaches, enabling tailored treatment options that cater to individual patient needs. This trend emphasizes a move towards long-term, personalized management strategies, enhancing patient outcomes and quality of life. As new therapeutic modalities continue to evolve, the market is poised for substantial growth and expansion, attracting interest from various stakeholders across the healthcare landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Cystic Fibrosis Market Size by Treatment Method & CAGR (2025-2032)

Market Overview
Medication
Devices

Global Cystic Fibrosis Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Inhaled

Global Cystic Fibrosis Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Pancreatic Enzyme Supplements
Mucolytic, Bronchodilators
Antibiotics
CFTR Modulators

Global Cystic Fibrosis Market Size & CAGR (2025-2032)

North America (Treatment Method, Route of Administration, Drug Class)
- US
- Canada
Europe (Treatment Method, Route of Administration, Drug Class)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Method, Route of Administration, Drug Class)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Method, Route of Administration, Drug Class)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Method, Route of Administration, Drug Class)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Vertex Pharmaceuticals Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi Farmaceutici S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcresta Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laurent Pharmaceuticals Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pulmocide Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zambon S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Translate Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Armata Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

嚢胞性線維症の市場規模、シェア、成長分析、治療方法別、投与経路別、薬剤クラス別、地域別 - 産業予測、2025年～2032年

Cystic Fibrosis Market Size, Share, and Growth Analysis, By Treatment Method (Medication, Devices), By Route of Administration (Oral, Inhaled), By Drug Class, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

嚢胞性線維症市場規模：治療方法別& CAGR（2025-2032）

嚢胞性線維症市場規模：投与経路別& CAGR（2025-2032）

嚢胞性線維症市場規模：薬剤クラス別& CAGR（2025-2032）

嚢胞性線維症市場規模：地域別& CAGR（2025-2032）